keynote-199: an update on pembrolizumab for mcrpc
Published 4 years ago • 237 plays • Length 3:18Download video MP4
Download video MP3
Similar videos
-
2:54
updated analysis of keynote-199: pembrolizumab for mcrpc previously treated with docetaxel
-
2:35
keynote 199 cohorts 4 & 5: enzalutamide and pembrolizumab for mcrpc
-
4:15
keynote-365: pembrolizumab combination therapy for mcrpc
-
1:21
keynote-921: pembrolizumab plus docetaxel in chemotherapy-naïve mcrpc
-
2:39
prospects and progress of treatments for mcrpc
-
3:51
talabostat combined with pembrolizumab in men with mcrpc
-
1:05
combining a dna vaccine with pembrolizumab for mcrpc
-
1:00
adjuvant pembrolizumab in kidney cancer from keynote 564
-
1:22
updated outcomes of keynote-010 of pembrolizumab for nsclc
-
1:14
dr. yu on combining pembrolizumab and olaparib in mcrpc
-
2:22
keynote-057: extended follow-up of pembrolizumab in bladder cancer
-
4:14
keynote-585: perioperative pembrolizumab in stomach cancers
-
1:07
dr. penson on treatment selection in metastatic hormone-sensitive prostate cancer
-
2:50
prosper: enzalutamide vs. placebo for nmcrpc
-
3:18
#esmo21 highlights on combination of pembrolizumab plus chemotherapy in mtnbc: the keynote-355 study
-
3:02
updates from keynote 57: pembrolizumab for patients with bladder cancer
-
4:34
emerging treatments for mcrpc
-
1:09
keynote-224: improving hcc outcomes with pembrolizumab